ASCORBIC ACID

Post-LOE

ascorbic acid

ANDAINTRAVENOUSSOLUTION
Approved
Aug 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

(a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to restore the body pool of ascorbic acid.

Pharmacologic Class:

Vitamin C

Clinical Trials (5)

NCT03697239Phase 1/2Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started Jun 2019
0
Metastatic Pancreatic CancerPancreatic CancerPancreas Cancer+3 more
NCT03908333Phase 1/2Withdrawn

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started May 2019
0
Metastatic Pancreatic CancerPancreatic CancerPancreas Cancer+3 more
NCT03797443Phase 1/2Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started Jan 2019
0
Metastatic Pancreatic Cancer
NCT03334409Phase 2Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Started Feb 2018
5 enrolled
Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+2 more
NCT03410030Phase 1/2Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Started Dec 2017
27 enrolled
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma Resectable+2 more